CALCA and migraine disorder: mAbs targeting the calcitonin gene‐related peptide (CGRP) pathway, such as eptinezumab, fremanezumab, galcanezumab, and erenumab, have emerged as a significant advancement in migraine prophylaxis (Table 1 illustrates their mechanisms of action).